Movement Alert|Smoore International Falls 3.46% in Regular Trading, Profit-Taking Continues After FDA-Driven Rally of Over 20%

Market Focus05-28

On May 28, Smoore International fell 3.46% in regular trading, trading at HK$9.2 per share, with trading volume of HK$25.42 million.

On the news front, the U.S. FDA previously approved non-tobacco flavored e-cigarettes through PMTA review for the first time, pushing the stock up over 20% within the month. However, since May 14 the stock has been in continuous pullback. A brief stabilization and rebound on May 22 failed to hold, and the stock has resumed its downward drift. The current decline reflects ongoing profit-taking pressure, with notably shrinking trading volumes indicating strong wait-and-see sentiment among market participants.

Institutional analysts remain constructive on Smoore International's medium-to-long-term outlook, noting that the company's underage-user identification technology was a key consideration in the FDA approval process. Core client products and proprietary brands are expected to accelerate their regulatory approvals, positioning the company to directly benefit from a recovery in the compliant e-cigarette market.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment